COVID-19: Time for Post-Exposure Prophylaxis?

Ivan Gentile, Alberto Enrico Maraolo, Prisco Piscitelli and Annamaria Colao
Additional contact information
Ivan Gentile: Department of Clinical Medicine and Surgery–Section of Infectious Diseases, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
Alberto Enrico Maraolo: Department of Clinical Medicine and Surgery–Section of Infectious Diseases, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
Prisco Piscitelli: UNESCO Chair for Health Education and Sustainable Development, University of Naples Federico II, 80131 Naples, Italy
Annamaria Colao: UNESCO Chair for Health Education and Sustainable Development, University of Naples Federico II, 80131 Naples, Italy

IJERPH, 2020, vol. 17, issue 11, 1-3

Abstract: From a healthcare perspective, infection due to the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and the ensuing syndrome called COVID-19 (coronavirus disease 2019) represents the biggest challenge the world has faced in several decades. Particularly worrisome are the high contagiousness of the virus and the saturation of hospitals’ capacity due to overwhelming caseloads. Non-pharmaceutical interventions such as quarantine and inter-personal distancing are crucial to limiting the spread of the virus in the general population, but more tailored interventions may be needed at an individual level on a case-by-case basis. In this perspective, the most insidious situation is when an individual has contact with a contagious subject without adequate protection. If rapidly recognized afterwards, this occurrence may be promptly addressed through a post-exposure chemoprophylaxis (PEP) with antiviral drugs. This strategy has been implemented for other respiratory viruses (influenza above all) and was successfully used in South Korea among healthcare workers against the Middle East respiratory syndrome (MERS) coronavirus, by providing people who were exposed to high-risk contacts with lopinavir-ritonavir plus ribavirin. Initial experiences with the use of hydroxychloroquine to prevent COVID-19 also seem promising. Post-exposure chemoprophylaxis might help mitigate the spread of SARS-CoV-2 in the current phase of the COVID-19 pandemic.

Keywords: COVID-19; post-exposure; healthcare; prophylaxis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/11/3997/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/11/3997/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:11:p:3997-:d:367383

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().